{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:01:38Z","timestamp":1785279698118,"version":"3.55.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.coviro.2011.07.007","type":"journal-article","created":{"date-parts":[[2011,8,17]],"date-time":"2011-08-17T03:48:54Z","timestamp":1313552934000},"page":"268-279","source":"Crossref","is-referenced-by-count":16,"title":["Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer"],"prefix":"10.1016","volume":"1","author":[{"given":"Ian H","family":"Frazer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron J","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Pt 5","key":"10.1016\/j.coviro.2011.07.007_bib0005","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1099\/vir.0.82732-0","article-title":"Betapapillomaviruses frequently persist in the skin of healthy individuals","volume":"88","author":"de Koning","year":"2007","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2011.07.007_bib0010","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.20244","article-title":"Against which human papillomavirus types shall we vaccinate and screen? The international perspective","volume":"111","author":"Munoz","year":"2004","journal-title":"Int J Cancer"},{"issue":"9 Suppl. HPV","key":"10.1016\/j.coviro.2011.07.007_bib0015","first-page":"S3","article-title":"Natural history of HPV infections","volume":"58","author":"Wright","year":"2009","journal-title":"J Fam Pract"},{"issue":"Suppl. 10","key":"10.1016\/j.coviro.2011.07.007_bib0020","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1016\/j.vaccine.2008.05.064","article-title":"Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia","volume":"26","author":"Bosch","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2011.07.007_bib0025","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/oxfordjournals.jncimonographs.a003483","article-title":"Chapter 8: human papillomavirus and skin cancer","volume":"2003","author":"Pfister","year":"2003","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.coviro.2011.07.007_bib0030","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0738-081X(96)00154-X","article-title":"HPV infections and immunosuppression","volume":"15","author":"Bouwes Bavinck","year":"1997","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.coviro.2011.07.007_bib0035","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/rmv.488","article-title":"Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity","volume":"16","author":"Hebner","year":"2006","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.coviro.2011.07.007_bib0040","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1128\/JVI.67.3.1373-1384.1993","article-title":"Tumorigenicity by human papillomavirus type 16 E6 and E7 in transgenic mice correlates with alterations in epithelial cell growth and differentiation","volume":"67","author":"Griep","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2011.07.007_bib0045","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/ijc.21394","article-title":"Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia","volume":"118","author":"Van Poelgeest","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coviro.2011.07.007_bib0050","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/jnci\/81.22.1698","article-title":"Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer","volume":"81","author":"Jochmus-Kudielka","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.coviro.2011.07.007_bib0055","first-page":"1934","article-title":"Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites","volume":"61","author":"Carter","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.coviro.2011.07.007_bib0060","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection","volume":"181","author":"Carter","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2011.07.007_bib0065","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1128\/JVI.02726-07","article-title":"Arrangement of L2 within the papillomavirus capsid","volume":"82","author":"Buck","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2011.07.007_bib0070","doi-asserted-by":"crossref","first-page":"9503","DOI":"10.1128\/JVI.79.15.9503-9514.2005","article-title":"Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers","volume":"79","author":"Orozco","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2011.07.007_bib0075","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1097-2765(00)80449-9","article-title":"Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16","volume":"5","author":"Chen","year":"2000","journal-title":"Mol Cell"},{"key":"10.1016\/j.coviro.2011.07.007_bib0080","article-title":"Evaluation of quadrivalent HPV 6\/11\/16\/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection","volume":"5","author":"Olsson","year":"2009","journal-title":"Hum Vac"},{"key":"10.1016\/j.coviro.2011.07.007_bib0085","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.virol.2008.11.046","article-title":"Papillomaviruses in the causation of human cancers\u2014a brief historical account","volume":"384","author":"zur Hausen","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2011.07.007_bib0090","doi-asserted-by":"crossref","first-page":"c1804","DOI":"10.1136\/bmj.c1804","article-title":"Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme","volume":"340","author":"Anttila","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.coviro.2011.07.007_bib0095","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0042-6822(91)90772-4","article-title":"Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles","volume":"185","author":"Zhou","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2011.07.007_bib0100","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/S0140-6736(06)68921-6","article-title":"Finding a vaccine for human papillomavirus","volume":"367","author":"Frazer","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2011.07.007_bib0105","doi-asserted-by":"crossref","first-page":"6929","DOI":"10.1128\/JVI.67.12.6929-6936.1993","article-title":"Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles","volume":"67","author":"Kirnbauer","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2011.07.007_bib0110","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1086\/320190","article-title":"A phase 1 study of a recombinant virus like particle vaccine against human papillomavirus type 11 in healthy adult volunteers","volume":"183","author":"Evans","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2011.07.007_bib0115","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/jnci\/djg018","article-title":"Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles","volume":"95","author":"Nardelli-Haefliger","year":"2003","journal-title":"JNCI-J Natl Cancer Inst"},{"key":"10.1016\/j.coviro.2011.07.007_bib0120","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1073\/pnas.92.25.11553","article-title":"Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas","volume":"92","author":"Suzich","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1 Suppl.","key":"10.1016\/j.coviro.2011.07.007_bib0125","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ygyno.2010.04.004","article-title":"Current understanding of the mechanism of HPV infection","volume":"118","author":"Schiller","year":"2010","journal-title":"Gynaecol Oncol"},{"key":"10.1016\/j.coviro.2011.07.007_bib0130","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1086\/514105","article-title":"Human papillomavirus type II (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast","volume":"176","author":"Lowe","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2011.07.007_bib0135","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1006\/viro.2000.0272","article-title":"Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes","volume":"270","author":"Roden","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2011.07.007_bib0140","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2011.07.007_bib0145","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.ogx.0000160577.38368.c4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized, controlled trial","volume":"60","author":"Harper","year":"2005","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.coviro.2011.07.007_bib0150","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coviro.2011.07.007_bib0155","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2011.07.007_bib0160","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2011.07.007_bib0165","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials","volume":"369","author":"Ault","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2011.07.007_bib0170","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2011.07.007_bib0175","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Munoz","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.coviro.2011.07.007_bib0180","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24\u201345 years: a randomised, double-blind trial","volume":"373","author":"Munoz","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2011.07.007_bib0185_1","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2011.07.007_bib0190","doi-asserted-by":"crossref","first-page":"A46","DOI":"10.1016\/j.vaccine.2008.10.085","article-title":"Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence","volume":"27 Suppl. 1","author":"Bonanni","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2011.07.007_bib0195","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 virus like particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.coviro.2011.07.007_bib0200","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","article-title":"Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine","volume":"25","author":"Olsson","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2011.07.007_bib0205_1","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1016\/j.vaccine.2008.09.073","article-title":"HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine","volume":"26","author":"Joura","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2011.07.007_bib0210","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1016\/j.vaccine.2010.02.019","article-title":"Post-licensure monitoring of HPV vaccine in the United States","volume":"28","author":"Markowitz","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2011.07.007_bib0215_1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1503\/cmaj.080916","article-title":"Anaphylaxis following quadrivalent human papillomavirus vaccination","volume":"179","author":"Brotherton","year":"2008","journal-title":"CMAJ"},{"key":"10.1016\/j.coviro.2011.07.007_bib0220_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(10)70225-5","article-title":"Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data","volume":"11","author":"Donovan","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2011.07.007_bib0225","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1016\/j.vaccine.2010.04.070","article-title":"A summary of the post-licensure surveillance initiatives for GARDASIL\/SILGARD((R))","volume":"28","author":"Bonanni","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2011.07.007_bib0230","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1016\/j.vaccine.2010.02.057","article-title":"Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types","volume":"28","author":"Zhang","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2011.07.007_bib0235","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/INF.0b013e3181e28e6e","volume":"29","author":"Vesikari","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.coviro.2011.07.007_bib0240_1","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2011.07.007_bib0245","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.coviro.2011.07.007_bib0250","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJM199607043350107","article-title":"Postherpetic neuralgia\u2014pathogenesis, treatment, and prevention","volume":"335","author":"Kost","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2011.07.007_bib0255","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/11317560-000000000-00000","article-title":"Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans","volume":"27","author":"White","year":"2009","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.coviro.2011.07.007_bib0365_1","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/j.1532-5415.2010.03021.x","article-title":"Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults","volume":"58","author":"Schmader","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.coviro.2011.07.007_bib0265","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1086\/599381","article-title":"Viremia in acute herpes zoster","volume":"200","author":"Satyaprakash","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2011.07.007_bib0370_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/653605","article-title":"Zoster vaccine: current status and future prospects","volume":"51","author":"Oxman","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2011.07.007_bib0275","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.1128\/JVI.77.12.6979-6987.2003","article-title":"Varicella-zoster virus DNA in cells isolated from human trigeminal ganglia","volume":"77","author":"Levin","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2011.07.007_bib0280","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1128\/JCM.00874-07","article-title":"Effect of viral load on the outcome of herpes zoster","volume":"45","author":"Quinlivan","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.coviro.2011.07.007_bib0285","series-title":"Transplant Infections","first-page":"391","article-title":"Herpes simplex and varicella-zoster virus infection after hematopoietic stem cell or solid organ transplantation","author":"Gnann","year":"2010"},{"key":"10.1016\/j.coviro.2011.07.007_bib0290","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1016\/S0264-410X(03)00303-7","article-title":"Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay","volume":"21","author":"Takahashi","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2011.07.007_bib0375_1","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1086\/651199","article-title":"Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses","volume":"201","author":"Weinberg","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2011.07.007_bib0300","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0891-5520(05)70319-6","article-title":"The varicella vaccine. Prevention of herpes zoster","volume":"10","author":"Levin","year":"1996","journal-title":"Infect Dis Clin N Am"},{"key":"10.1016\/j.coviro.2011.07.007_bib0305","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jpain.2004.06.001","article-title":"Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory","volume":"5","author":"Coplan","year":"2004","journal-title":"J Pain"},{"key":"10.1016\/j.coviro.2011.07.007_bib0310","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/jmv.21506","article-title":"A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses","volume":"81","author":"Harbecke","year":"2009","journal-title":"J Med Virol"},{"key":"10.1016\/j.coviro.2011.07.007_bib0315_1","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2011.07.007_bib0320_1","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1086\/605611","article-title":"Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine","volume":"200","author":"Weinberg","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2011.07.007_bib0325","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev-immunol-031210-101308","article-title":"Prevention and treatment of papillomavirus-related cancers through immunization","volume":"29","author":"Frazer","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.coviro.2011.07.007_bib0330","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1525-1497.2005.0150.x","article-title":"The incidence of herpes zoster in a United States administrative database","volume":"20","author":"Insinga","year":"2005","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.coviro.2011.07.007_bib0335","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1016\/j.vaccine.2006.02.017","article-title":"The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination","volume":"24","author":"de Melker","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2011.07.007_bib0340","first-page":"9","article-title":"The nature of herpes zoster: a long-term study and a new hypothesis","volume":"58","author":"Hope-Simpson","year":"1965","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.coviro.2011.07.007_bib0345","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.vaccine.2008.11.012","article-title":"Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older","volume":"27","author":"Stein","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2011.07.007_bib0350","doi-asserted-by":"crossref","first-page":"612","DOI":"10.2340\/00015555-0729","article-title":"Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006","volume":"89","author":"Jih","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.coviro.2011.07.007_bib0355","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1017\/S0950268801005921","article-title":"Epidemiology of varicella zoster virus infection in Canada and the United Kingdom","volume":"127","author":"Brisson","year":"2001","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.coviro.2011.07.007_bib0360","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/S0264-410X(02)00180-9","article-title":"Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox","volume":"20","author":"Brisson","year":"2002","journal-title":"Vaccine"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625711000617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625711000617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T09:54:37Z","timestamp":1592819677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625711000617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S1879625711000617"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2011.07.007","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}